CARA - Cara Therapeutics

-

$undefined

N/A

(N/A)

Cara Therapeutics NasdaqCM:CARA Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Location: 400 Atlantic Street, Stamford, CT, 06901, United States | Website: https://www.caratherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

30.88M

Cash

37.9M

Avg Qtr Burn

-15.23M

Short % of Float

1.70%

Insider Ownership

13.07%

Institutional Own.

24.17%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Korsuva IV (CR845 IV) Details
Pruritus with chronic kidney disease , Kidney disease

Approved

Quarterly sales

Oral Korsuva (difelikefalin) (CR845) Details
Chronic liver disease, Liver disease, Chronic pruritus, Hemophilia, Blood disorder

Failed

Discontinued

Oral Korsuva (difelikefalin) (CR845) Details
Chronic pruritus, Pruritus associated with notalgia paresthetica

Failed

Discontinued

Oral Korsuva (difelikefalin)(CR845) Details
Inflammatory disease, Skin disease/disorder, Atopic dermatitis, Atopic pruritus

Failed

Discontinued

Oral Korsuva (difelikefalin) (CR845) Details
Pruritus with chronic kidney disease , Chronic kidney disease

Failed

Discontinued